Modafi nil, is a wake-promoting drug approved by Food and Drugs Administration (FDA) for narcolepsy and sleep-apnoe syndrome. Although the mechanism underlying its arousal action remains elusive, it is known to increase glutamatergic, histaminergic, noradrenergic and dopaminergic transmission and decrease GABA release in different regions of the brain, which are all known to be involved in pathophysiology of epilepsy. In the present study, the effects of modafi nil on pentylenetetrazol (PTZ) induced convulsive epilepsy were investigated in rats. Five experimental groups were formed for this purpose and each group was administered fi ve different doses of modafi nil (1, 2, 4, 45, 180 mg/kg, i.p) for seven days. All groups were administered PTZ (80 mg/kg, i.p) 2 hours after the fi nal dose and the epileptic seizure activity was evaluated. According to the results; we detected that modafi nil delayed the onset of the fi rst myoclonic jerk and decreased the total major seizure period between 2-180 mg/kg doses and did not affect the major seizure onset period at any of the doses administrated. These results imply that modafi nil exerts a dose dependent antiepileptic effect on PTZ induced convulsive epilepsy in rats (Tab. 1, Fig. 3, Ref, 42) . Text in PDF www.elis.sk.
Introduction
Epilepsy is a serious neurobehavioral disorder characterized by recurrent seizures, presenting with episodes of sensory, motor or autonomic symptoms with or without loss of consciousness (Sridharan, 2002) . Epileptogenesis is closely related to an imbalance between GABAergic and glutamatergic activity in different regions of the brain (Dalby et al, 2001 ). Impairment of GABAmediated inhibitory and glutamate-mediated excitatory circuits has been implicated in different forms of epilepsy in experimental animal models and in human studies. On the other hand, epilepsy has a complex association with sleep. Most of the epilepsy patients complain from sleep disturbance and also sedative and cognitive adverse effects of the antiepileptic drugs. A large number of experimental models of seizure and epilepsy have been developed to understand basic mechanisms underlying epileptogenesis (Bambal et al, 2011) . Pentylenetetrazol (PTZ) is a systemic convulsive agent, which is generally used to form experimental epilepsy models. It is the selective GABA-A receptor channel blocker and is related with decrease of GABA-mediated neurotransmission (Bambal et al, 2011) . In low doses, it induces typical changes in the EEG characterised by short-lasting trains of spike and waves at 5 ± 7 Hz frequency with no clear overt behavioural response. In higher (> 40 mg/kg; ip) doses, however, PTZ induces clear behavioural responses (Klioueva et al, 2000) . Behavioural scoring is commonly used to access seizure intensity in PTZ model of epilepsy.
Modafi nil, (RS)-2-(Diphenylmethylsulfi nyl)acetamide, a well known wake promoting drug, has been in use of daytime sleepiness in the patients of narcolepsy for a few years. It improves wakefulness in a variety of species and is effi cacious in humans with few peripheral or central side effects. Modafi nil is theorised to work in a localised manner. The mechanisms underlying its clinical effects are complex and not similar with the other wake-promoting agents. Researchers have not been able to isolate a specifi c site of action or locate a major receptor binding. Therefore, modafi nil is still an agent in search of a mechanism. Several in vivo and in vitro studies suggest that modafi nil demonstrates an increase in glutamatergic, noradrenergic and dopaminergic transmission in specifi c parts of the brain, and also activates histaminergic tuberomammillary nucleus via inhibition of GABA release (MurilloRodriguez et al, , Scammell et al, 2000 , which are all known to be involved in pathophysiology of epilepsy. However, its use in epileptic patients is limited due to safety suspicions.
This study aimed to examine the effects of modafi nil on behavioural results of PTZ-induced convulsive epilepsy in rats.
Material and methods

Subjects
Adult male Wistar rats weighting 200-250 g were used throughout this study after at least 1 week of aclimatisation. All described procedures were approved by the local ethics committee. Animals were housed in groups of 3-4 and were allowed free access to food and water. All animals were kept in a temperature controlle d (22 ± 1 °C) environment on a 12-h light/dark cycle.
Experimental groups
Rats were assigned to the following experiment groups and each animal group was composed of seven rats:
Group1: Serum physiologic (SF) (1 week; i.p) 
Statistical analysis
All statistical procedures were performed using the SPSS statistical software package (version: 12.0). The differences between the groups were analysed with one-way ANOVA. Signifi cant differences were further evaluated with the Post hoc LSD test. Data are expressed as the means ± standard error of the mean (SEM). Statistical signifi cance was set at p < 0.05.
Results
Seizure activity was evaluated with the behavioural changes including fi rst myoclonic jerk, sudden muscular spasm accompanying tail movements and head shivering. The excitation of the anterior and posterior extremities following the clonic jerks with clonus of facial and anterior extremity muscles and also a loss of rearing refl ex was determined as the onset of the generalized seizure and the time passed from the onset of generalized seizure to regaining of the rearing refl ex was determined as total period of generalized seizure.
Latencies for the onset of fi rst myoclonic jerk; were 110 ± 35 sn in the control group and 122 ± 81 sn, 200 ± 59 sn, 205 ± 57 sn, 210 ± 119 sn, 194 ± 63 sn in the 1 mg/kg, 2 mg/kg, 4 mg/kg, 45 mg/kg and 180 mg/kg modafi nil administrated groups; respectively (Tab. 1). The detention of the fi rst myoclonic jerk was statistically signifi cant in 2, 4, 45, 180 mg/kg modafi nil administrated groups, compared to the control group; respectively (p < 0.05). Also there was a signifi cant difference in the latencies for the onset of fi rst myoclonic jerks of 4 mg/kg and 45 mg/kg modafi nil administrated groups compared to 1 mg/kg modafi nil administrated group (p < 0.05) (Fig. 1) .
Latencies for the onset of generalized seizure; were 269 ± 165 sn in the control group and 388 ± 270 sn, 595 ± 363 sn, 483 ± 234 sn, 436 ± 324 sn and 521 ± 292 sn in the 1 mg/kg, 2 mg/kg, 4 mg/kg, 45 mg/kg and 180 mg/kg modafi nil administrated groups; respectively (Tab. 1). There was no statistically signifi cant difference between any of the groups (Fig. 2) regarding the latencies for the onset of generalised seizures.
Total length of generalized seizures; were 1136 ± 503 sn in the control group and 669 ± 799 sn, 437 ± 527 sn, 359 ± 388 sn, 503 ± 486 sn, 200 ± 355 sn in the 1 mg/kg, 2 mg/kg, 4 mg/kg, 45 mg/kg and 180 mg/kg modafi nil administrated groups; respectively (Tab. 1). The reduction in the total period of generalized seizures were found statistically signifi cant in 2, 4, 45, 180 mg/ kg modafi nil administrated groups; compared to the control group (p < 0.05) (Fig. 3) .
Discussion
Results of the present study indicate that; modafi nil generates a dose depended anticonvulsant effect on PTZ-induced epileptic activity in rats. It is both effective on reducing severity of seizures and extending the latency of the convulsive activity, but it has no effect on the major seizure onset period.
Previous studies indicate that modafi nil activates adrenergic and dopaminergic receptors, increases histamin and glutamate release and also inhibits GABAergic activity in different regions of the brain (Chen et al (2007); investigated the effects of modafi nil ( 22.5, 45, 90 and 180 mg/kg, ip) on PTZ-kindling and maximal electroshock (MES) seizures, they showed that it signifi cantly decreased the incidence of tonic hind leg extension in MES seizure and protected against PTZ induced convulsive behaviours in 22.5, 45 and 90 mg/kg doses. In addition, modafi nil at 180 mg/kg dose exerted an antiepileptic effect in the MES model, but increased the seizure stage in the PTZkindling model. They also demonstrated that the antiepileptic effect of modafi nil was antagonized by the adrenergic α 1 receptor antagonist in the MES model and by either adrenergic α 1 and histaminergic H1 antagonists in the PTZ-kindling model. The anticonvulsant effects of modafi nil at low doses (22.5, 45 and 90 mg/kg) presented in this study are compatible with the results of the present study. However, the effects of high dose (180 mg/kg) of modafi nil in PTZ-kindling model is in contradiction with our results. In previous studies, modafi nil was shown to modulate noradrenalin transporter (Madras et al, 2006) , block noradrenalin re-uptake (Gallopin et al, 2004 ) and as a result, increase central noradrenergic transmission (Duteil et al, 1990) . In many studies adrenergic α 1 receptor activation was shown to have anticonvulsant effects, whereas α 1 receptor inhibition is proconvulsant (Chauvel and Trottier, 1986 , Weinshenker and Szot, 2002 , Wisor and Eriksson, 2005 .
It has been suggested that histamin might have a role in termination of epileptic seizures by similar way with opioids (Yokoyama et al, 1992) . H1R has been reported to mediate the anticonvulsive effect of histam ine (Kamei et al, 1998) . H1R antagonists, such as pyrilamine, diphenhydramine, methapyrilene, and chlorpheniramine, are brain-penetrating drugs with sleeppromoting effects and induce seizure in human beings and rats (Kamei et al, 2000) , accelerate rat kindling seizures (Yokoyama et al, 1996) , and lower the mouse PTZ seizure threshold. Jin et al (2004) ; investigated the effects of the fi rst-generation H1 receptor antagonist; dipenhydramine and the second generation H1 receptor antagonist; fexofenadine on PTZ-induced kindling seizures. They demonstrated that diphenhydramine signifi cantly enhanced the seizure severity, compared to fexofenadine. They concluded that seizure development of PTZ-induced kindling is promoted by the fi rst-but not the second generation histamine H1 antagonists via the blockade of brain histamine H1 receptor. Modafi nil signifi cantly increases histamine release and enhances c-fos immunoreactivity (a gene that is transcribed by the factors that cause growth and differentiation by affecting cells) in the tuberomammillary nucleus (Ishizuka et al, 2003 , Scammell et al, 2000 . Tuberomamillary nucleus is the neuronal source of histamine and these neurons are essential for wake promoting (Lin et al, 1994) . Ishizuka et al. demonstrated that intracerebroventricular injection of modafi nil increased histamine levels but direct injection of modafi nil to the tuberomamillary nucleus did not stimulate histamin release (Ishizuka et al, 2003) . Nishida et al (2007) reported that deep brain stimulation targeted to the tuberomammillary nucleus inhibited PTZ-induced seizure in rats. They also detected that the antiepileptic effect of deep brain stimulation to the tuberomammillary nucleus was also blocked by H1R antagonist. They concluded that; tuberomamillary nucleus; a sole region where cell bodies of the histaminergic neurons are located, activates the histaminergic system and induces desynchronization to inhibit PTZ-induced seizure in rats.
There is lot of evidence that modafi nil also enhances dopaminergic transmission by connecting weakly to dopamin carriers (Mignot et al, 1994 , Dopheide et al, 2007 . Recent studies have shown that dopamine receptor agonists induce expression of Foslike immunoreactivity in rat striatal neurons. Studies carried by using dopamin agonists or drugs which enhance dopaminergic transmission such as amfetamine demonstrated that fos protein levels increased in all regions where modafi nil increased c-fos immunoreactivity. (Cole et al, 1992 , Wirtshafter, 1998 . Ferraro et al (1996) used dual prob microdialysis method for investigating effects of modafi nil on GABA release in 3 different regions of the brain (striatum, globus pallidus ve substansia nigra) and they demonstrated that modafi nil decreases GABA released in striatal and pallidal regions, but did not affect GABA levels in nigral region. They also showed that modafi nil enhances glutamate release in lower regions of thalamus (Ferraro et al, 1998) . Previous microdialysis studies using a similar microdialysis preparation in an awake rat have shown that modafi nil reduced GABA release in the medial preoptic area and posterior hypothalamus but not in two discrete subregions of the thalamus where conversely the drug enhanced glutamate release (Ferraro et al, 1996) . A proton study using two dimensional NMR spectroscopy in the rat has shown that modafi nil increased the level of aspartate and the glutamateglutamine pool in the cortex. A complementary microdialysis study has demonstrated the occurrence of a moderate transitory increase, followed by a prolonged decrease, in the level of extracellular glutamate in the rat brain cortex. We can conclude that acute and chronic effects of modafi nil on glutamate-GABA balance are different. In the present study, we examined the chronic effects of modafi nil after 1 week administration. Accordingly, we can say that the chronic decrease in glutamate levels during the modafi nil administration period may be responsible from its antiepileptic effect.
On the other hand, previous laboratory studies have shown that modafi nil has antioxidative and neuroprotective effects, which can also be related to its antiepileptic effects. The primary site of action of modafi nil's antioxidant effects is unknown, but it is possible to directly act on enzymes in the free radical scavenging system of the brain and reduce free radical levels. Xiao et al (2004) investigated the effects of modafi nil on the oxidative stress induced by MPTP exposure in mice brain. They demonstrated that modafi nil increased the reduced levels of glutathione and reduced the increased levels of lipid peroxidation products in MPTP damaged neurons. Antonelli et al (1998) showed that modafi nil prevented glutamate cytotoxicity in cultured cortical neurons. Modafi nil was shown to prevent the reduction in GABA release in the cells exposed to glutamate, but had no effects on GABA levels of the cells not exposed to glutamate. The neuroprotective properties of modafi nil may be linked to the prolonged decrease in extracellular glutamate levels. Convulsive epilepsies also cause a similar glutamate cytoxicity and neuroprotective effects of modafi nil may be another possible way to prevent these seizures.
According to the data obtained from this study, we can conclude that modafi nil is able to increase the seizure thres hold and to attenuate the severity of seizures in PTZ induced convulsive epilepsy in rats. We think that, modafi nil may be a potential antiepileptic drug in some kinds of epileptic seizures, at least it may increase the effectiveness of the novel antiepileptics or attenuate their side-effects when coadministrated. Further investigations both with animal and human studies are needed to demonstrate the molecular bases of modafi nil's antiepileptic effects.
Conclusion
These results imply that modafi nil can show a dose dependent antiepileptic effect on pentylenetetrazol-induced convulsive epilepsy in rats.
